Hualan Biological Vaccine Third Quarter 2024 Earnings: EPS: CN¥0.41 (vs CN¥0.87 in 3Q 2023)

Hualan Biological Vaccine (SZSE:301207) Third Quarter 2024 Results

Key Financial Results

• Revenue: CN¥921.8m (down 41% from 3Q 2023).
• Net income: CN¥242.1m (down 54% from 3Q 2023).
• Profit margin: 26% (down from 33% in 3Q 2023). The decrease in margin was driven by lower revenue.
• EPS: CN¥0.41 (down from CN¥0.87 in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hualan Biological Vaccine Earnings Insights

Looking ahead, revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are down 1.1% from a week ago.

Valuation

Our analysis of Hualan Biological Vaccine based on 6 different valuation metrics shows it might be undervalued. To access our thorough examination of analyst consensus click here and discover the expected future direction of the company.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.